

Digital Pathology Adoption Curve in the U.S. and Globally... What's Coming Next

Joseph Mossel CEO and Co-Founder

May 1st, 2024




## My journey to digital pathology & Al





Clinical grade, Al-powered platform for cancer diagnostics







### Prepared to climb insurmountable cliffs









### Pathologists are advocating for Ibex





Germany: Dr. Niedobitek, Sana



Brigham & Women's: Prof. Schnitt



Quest Diagnostics: Dr. Borkowski




#### UK/NHS Wales: Dr. Aslam



Germany: Prof. Ströbel, UMG





Israel: Dr. Sukmanov, Clalit

UPMC: Dr. Dhir





### 2016 Pathology Conference London

# "Digital Pathology is the future...


# and always will be..."



### The Business Case for Digital Pathology

Aug 11, 2016 | Analytical Software Systems, Cameras, Digital Imaging, Digital Pathology |

### Webinar: Making Your Business Case for Digital Pathology Adoption







# **"Digital** Pathology is here

## and always will be..."

### Europe is leading the way

KLAS reports Europe has the greatest adoption of digital pathology due to COVID-19 forcing the need for remote working options and to combat decreasing number of pathologists.

Govt. funding: UK, Germany, France, Nordics, etc.

### Systemic approach:


- Top-down approach to digital transformation in healthcare
- Government funding specifically for digital pathology and AI
- Collaboration between industry and medical community








## Digital Pathology journey in the UK





Single procurement process for all 25 PathLAKE member sites, enabling call-off of successfully awarded suppliers

Top scoring solutions for Breast Prostate Breast
 11 Trusts have selected Ibex Prostate AI



# Wales is the first country-wide deployment of DP AI

100% of prostate biopsies in Wales are reviewed using Ibex's Al





Dr. Muhammed Aslam Betsi Cadwaladr University Health Board, Wales Medipath, France's largest private laboratory network, deployed DP for Al cases




- ✓ 30+ laboratories in France
- ✓ Diagnosing 5,000+ prostate biopsies annually
- Pathologists were more efficient using Galen
  Prostate than using a microscope after
  reviewing only 40 cases






## Two approaches to adopting DP AI



### Adopt digital + AI at same time (application centric approach)



## U.S. adoption is accelerating

KLAS reports fewer than 10% of US organizations have adopted digital pathology for clinical use, and less than 5% of cases are signed out digitally.

### Key forces accelerating adoption

- COVID / remote work
- CPT Codes
- Driven by individual organizations
- Industry and healthcare professionals are



COLLEGE ₀f AMERICAN PATHOLOGISTS



The Ohio State University lead the U.S. in DP adoption and is now focusing on Al

- ✓ Went fully digital in 2020
- ✓ Pathologists have 3-screen "digital cockpit"
- ✓ Now introducing AI technologies













## CorePlus deployed complete DP AI workflow and leads the U.S. in AI-powered pathology

- ✓ Private reference lab in Puerto Rico
- ✓ 3,500+ prostate biopsies annually

- ✓ First in the U.S. to use AI in primary diagnosis
- ✓ 10,000+ cases analyzed using Ibex's AI





### Learn more about CorePlus tomorrow



Stepwise Introduction of AI and Image Analysis Algorithms into Daily Workflow and Primary Diagnosis

Mariano de Socarraz - CEO. CorePlus Thursday | May 2<sup>nd</sup> | Workshop 2



**Executive War College** On Diagnostics, Clinical Laboratory, and Pathology Management

April 30th - May 2nd, 2024 New Orleans, LA



Journal of Pathology Informatics Available online 30 April 2024, 100378 In Press, Journal Pre-proof (?) What's this?



Validation and three years of clinical experience in using an artificial intelligence algorithm as a second read system for prostate cancer diagnosis-real-world experience

Juan Carlos Santa-Rosario 🙎 🖂, Erik A. Gustafson, Dario E. Sanabria Bellassai, Phillip E. Gustafson, Mariano de Socarraz



### "We're here to impact people's lives"

- Mariano de Socarraz, CorePlus

### Misdiagnosis rates are up to 20%


### DP AI Impact

THE LANCET Digital Health

An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study

npj | breast cancer

Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies





## The future of DP AI adoption

Challenges

- Upfront investment with no reimbursement in place
- Lab transformation requires changes to IT, workflow and medical practice itself

## • Opportunities

- Transform the practice of pathology to give patients
  more accurate results faster
- Improved patient care can lead to downstream revenue and generate tangible ROI
- Early movers will achieve competitive advantage
- Recognize business value quicker with application centric deployment

We must come together to move forward and improve patient care

